T cell therapy: state-of-the-art -- Extending the use of adoptive T cell immunotherapy for infections and cancer -- Non-T cell therapeutic approaches -- B lymphocytes in cancer immunology -- Monoclonal antibody therapy for cancer -- Natural killer cells for cancer immunotherapy -- Dendritic cell-based cancer vaccines: practical considerations -- Mesenchymal stromal cells: an emerging cell-based pharmaceutical -- T cell therapeutic approaches -- Tumor-specific mutations as targets for cancer immunotherapy -- Counteracting subversion of MHC class II antigen presentation by tumors -- Mechanisms and implications of immunodominance in CD8 T-cell responses -- T regulatory cells and cancer immunotherapy -- Negative regulators in cancer immunology and immunotherapy -- Genetically engineered antigen specificity in T cells for adoptive immunotherapy -- Non-cellular aspects of cancer immunotherapy -- Cytokine immunotherapy -- Transcriptional modulation using histone deacetylase inhibitors for cancer immunotherapy -- Combining cancer vaccines with conventional therapies -- Combining oncolytic viruses with cancer immunotherapy -- Radiation therapy and cancer treatment: from the basics to combination therapies that ignite immunity -- Assessing immunotherapy through cellular and molecular imaging -- Transplantation -- Allogeneic and autologous transplantation therapy of cancer: converging themes.
0
SUMMARY OR ABSTRACT
Text of Note
Immunotherapy is now recognized as an essential component of treatment for a wide variety of cancers. It is an interdisciplinary field that is critically dependent upon an improved understanding of a vast network of cross-regulatory cellular populations and a diversity of molecular effectors; it is a leading example of translational medicine with a favorable concept-to-clinical-trial timeframe of just a few years. There are many established immunotherapies already in existence, but there are exciting new cancer immunotherapies just on the horizon, which are likely to be more potent, less toxic.